...
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Relugolix for the treatment of uterine fibroids
【24h】

Relugolix for the treatment of uterine fibroids

机译:Relugolix用于治疗子宫肌瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Uterine leiomyomas represent the most common form of benign gynecological tumors affecting 20-40% of women during their life. Several therapeutic options are available for treating these patients. The use of medical treatment for myomas has largely grown in the last years, in particular for women who would refuse, postpone or are not candidates for surgery. In the last years, the clinical investigation of gonadotropin-releasing hormone (GnRH) antagonists (GnRH-ants) has emerged. This class of drugs exerts pure competitive antagonistic activity on the GnRH receptor at the pituitary gland, producing an immediate stop in the release of gonadotropins and sex steroids. Relugolix is an orally active nonpeptide GnRH-ant, recently licensed for marketing in Japan for the treatment of symptoms related to uterine myomas. Currently, several phase III clinical trials are ongoing to evaluate this molecule in this setting in the U.S. and Europe.
机译:子宫平滑肌瘤代表最常见的良同妇科肿瘤,在生命中影响了20-40%的女性。 有几种治疗选择可用于治疗这些患者。 在过去几年中,使用医疗医疗的使用在很大一年里,特别是对于拒绝,推迟或不是手术候选人的女性而种植。 在过去几年中,出现了对促胆量释放激素(GNRH)拮抗剂(GNRH-Ants)的临床调查。 这类药物对垂体腺体的GNRH受体施加纯粹的竞争性拮抗活动,在促进促性腺激素和性类固醇中产生立即停留。 Relugolix是一个口头活跃的非肽GNRH-Ant,最近在日本营销销售,用于治疗与子宫肌瘤有关的症状。 目前,持续几期III期临床试验可在美国和欧洲的这种环境中评估该分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号